Dr. Samik Basu is currently the Director of Translational Sciences at Adaptimmune LLC. Prior to joining Adaptimmune, Dr. Basu co-led preclinical development efforts for Pembrolizumab (Keytruda) at Merck Research Laboratories in Boston, Massachusetts. He is a physician-scientist with 13 years of industry and academic experience in translational research, autoimmunity, and tumor immunology with prior roles at Merck, the National Institutes of Health, Albert Einstein College of Medicine, and the University of Pennsylvania. Dr. Basu received his MD from Temple University and completed residency training in Clinical Pathology.

Appearances:

﻿

DC Co-conference Day 3 April 5 @ 09:10

Panel: Engineering CAR-T & TCR cells for cancer therapy

How can you additionally modify T-cells beyond the T cell receptor/ the CAR to behave in a more controlled and/or potent fashion?

The challenge of keeping the manufacturing process simple, whilst maintaining the effectiveness of the product

The use of molecular imaging to track CAR T cells: Where do they go in the body? Do they accumulate in the tumor?

Jennifer Brogdon, Director of Exploratory Immuno Oncology,N.I.B.R.

Dr. Jennifer Brogdon is currently Director of Exploratory Immuno-Oncology at Novartis Institute for Biomedical Research, and has been instrumental in building the company’s preclinical CAR (chimeric antigen receptor) T cell therapy program for Oncology, which includes leading the research...

Dr Laurent Poirot, Head of Early Discovery,Cellectis

Laurent Poirot is an immunologist with over 13 years of experience in biotech.In graduate school, he studied immunology in the laboratory of Diane MATHIS and Christophe BENOIST (Université de Strasbourg, France and Harvard Medical School, Boston, MA). His PhD thesis focused on the pathogenic...

Dr Samik Basu, Director of Translational Sciences,Adaptimmune Llc

Dr. Samik Basu is currently the Director of Translational Sciences at Adaptimmune LLC. Prior to joining Adaptimmune, Dr. Basu co-led preclinical development efforts for Pembrolizumab (Keytruda) at Merck Research Laboratories in Boston, Massachusetts. He is a physician-scientist with 13 years of...

Dr Margo R. Roberts, Chief Scientific Officer,Kite Pharma Inc

Dr. Roberts has more than two decades of biomedical research, drug discovery and development experience. From 1999 to 2013, Dr. Roberts held an Associate Professor position at the University of Virginia where she pursued interdisciplinary research in the area of immunity and inflammation. From 1990 ...